2079results about "Metabolism disorder" patented technology

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The application discloses a fusion protein NGF2 with improved in-vivo half-life and application thereof, and belongs to the technical field of medical biological engineering, and comprises ABD and FGF2, and the gene and protein sequence thereof are respectively composed of the sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, and the complete gene and protein sequence thereof is shown in SEQ ID NO:4 and SEQ ID NO:8. The fusion protein NGF2 can keep activity for more than 7 days in an environment of 37 DEG C, and the half-life of the fusion protein in solution is prolonged. In addition, the ABD is combined with HAS to form a complex, and the total molecular weight reaches 90kDa, which is higher than the cut-off molecular weight of glomerular filtration, so that the in-vivo half-life of the fusion protein is effectively prolonged.

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

Provided herein are drug delivery systems and methods for locally delivering therapeutic agents, as well as methods for using such drug delivery systems for the treatment of disease.

To provide a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of a disease involving ATX.SOLUTION: The invention provides a carboxylic acid compound represented by the general formula (1), or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

Provided herein are isotopologues of MC4R agonist, processes for the preparation of the compounds, pharmaceutical compositions comprising the compounds, and methods of treating, managing, or preventing certain conditions, diseases, or disorders using the compounds or pharmaceutical compositions described herein.

The application discloses a kind of by polydopamine mesoporous nanoparticles crosslinked sulfhydrylated hyaluronic acid hydrogel and its preparation method and application, with dopamine and 4-formylphenylboronic acid as monomer, with trimethylbenzene as and poloxamer as template agent, in weak alkaline (pH=8.4), oxygen exists in the environment, by the oxidation self-polymerization reaction between monomer Preparation of polydopamine nanoparticles with mesoporous structure.Then the water dispersion of polydopamine nanoparticles is mixed with sulfhydrylated hyaluronic acid solution according to certain proportion, and the hydrogel dressing with injectable property is prepared.The hydrogel is expected to be used as skin wound dressing for the treatment of diabetic wounds.

The present disclosure generally relates to a method of treating lupus nephritis in a subject in need thereof. The method comprises determining that the subject has at least one of the following characteristics: an elevated C4x level, an elevated C4x / C4 ratio, a decreased C4 level, an elevated C1sC1 inhibitor level, an elevated C1sC1 inhibitor / C1s ratio, a decreased C1s level, an elevated C2b level, an elevated C2b / C2 ratio, a decreased C2 level, or an elevated pathogenic anti-C1q antibody 1 (PACA1) and / or pathogenic anti-C1q antibody 3 (PACA3) level, wherein C4x is selected from C4a, C4b, and C4d, and administering an inhibitor of the classical complement pathway to the subject.

The present disclosure relates to compositions and methods useful for the treatment and / or prevention of obesity and obesity-related diseases in a subject in need thereof. In various embodiments, the present disclosure relates to uses of compounds that are inhibitors of sphingosine kinase-2 (SphK2), dihydroceramide desaturase (DES1) and / or hexosylceramide synthase (GCS), such as opaganib, in the treatment and / or prevention of obesity and obesity-related diseases.

This invention relates to a chrysanthemum powder composition with fat-reducing effects and its preparation method, belonging to the field of fermentation product preparation technology. The method includes the following steps: S1: Chrysanthemum powder, lotus leaf powder, and kudzu root powder are sieved separately and mixed to obtain a mixed powder; S2: The mixed powder is soaked in purified water, subjected to ultrasonic pretreatment, sterilized by enzyme inactivation, and then cooled to obtain a plant-based liquid; S3: Epigallocatechin gallate (EGCG) is added to the plant-based liquid based on the dry weight of the raw materials, followed by inoculation with fermentation bacteria, and the mixture is stirred and dispersed evenly to obtain a fermentation system; S4: The fermentation system is subjected to static micro-anaerobic fermentation, with stirring during the process, to obtain a fermentation broth; S5: The fermentation broth is refrigerated and allowed to stand, centrifuged and filtered, then concentrated at low temperature, freeze-dried, and sieved to finally obtain the chrysanthemum powder composition with fat-reducing effects. The chrysanthemum powder composition prepared by this invention has a high viable bacteria count, good stability, and a significant fat-reducing effect.

Methods for preparing pyruvate kinase (PK) activators or salts or hydrates thereof are provided herein. Synthetic methods for preparing pyruvate kinase (PK) activators, or salts or hydrates thereof, are provided herein. Such activators may be prepared using compounds having formula (A-1) and / or formula (B-1). Specific PK activators and various intermediates prepared by and / or used by the synthetic methods described herein are also disclosed.

The application discloses a preparation method of ethanol extract of Drynaria Rhizome and application thereof. The method comprises the following steps: crushing and sieving Drynaria Rhizome, adding ethanol, reflux extraction, combining filtrates, vacuum concentration and drying, and thus the ethanol extract of Drynaria Rhizome is obtained. The in-vitro alpha-glucosidase enzyme inhibition experiment shows that the ethanol extract of Drynaria Rhizome has a significant inhibitory effect on alpha-glucosidase enzyme, and the IC 50 is about 142.68 μ g / mL. Therefore, the ethanol extract of Drynaria Rhizome can be used for preparing a hypoglycemic drug, health care product or functional food, and has a wide application prospect.

An additive for ruminant animal nutrition, comprising the following components: sodium hydroxide, calcium oxide, calcium hydroxide and sodium sulfate, along with an inert food-grade excipient, wherein said additive is to be added to ruminant animal feed in such a way that the pH of the feed is greater than 9. Ruminant feed comprising said additive for animal nutrition.

This invention relates to a composition comprising: i) a DPP-4 inhibitor selected from dandelion (Taraxacum officinale) extract, white mulberry (Morus alba) extract, bitter melon (Momordica charantia) extract, Saccharomyces cerevisiae hydrolysate, garlic (Allium sativum) extract, grape (Vitis vinifera) extract, turmeric (Curcuma longa) extract, moringa (Moringa oleifera) extract, and fenugreek (Trigonella foenum-graecum) extract; ii) a GLP-1 analog selected from Saccharomyces cerevisiae hydrolysate, white mulberry (Morus alba) extract, Paraguayan holly (Ilex paraguariensis) extract, Arabica coffee (Coffea arabica) extract, purslane (Portulaca oleracea) extract, and bitter melon (Momordica charantia) extract. The composition comprises: iii) an extract of *Momordica charantia*, *Lagerstroemia speciosa*, *Malus domestica*, *Cinnamomum verum*, and *Trigonella foenum-graecum*; and iii) a GLP-1 secretion promoter selected from inulin, gum arabic, *Momordica charantia*, *Portulaca oleracea*, *Berberis vulgaris*, *Coffea arabica*, *Angelica dahurica*, *Curcuma longa*, and *Trigonella foenum-graecum*, wherein at least one ingredient is selected from each of groups i) to iii), and at least three different ingredients are selected in total. The composition is intended to achieve at least one of the following effects: weight control, appetite reduction, satiety, calorie reduction, and reduction of glycemic spikes.

The application discloses a use of a pharmaceutical composition of a phenolic acid compound and probiotics, and particularly relates to a combination of chlorogenic acid and lactobacillus reuteri. The combination of chlorogenic acid and lactobacillus reuteri can improve glycolipid metabolic disorder, improve cognitive dysfunction, emotional disorder and delay aging, and can be used for preparing a medicine for treating metabolic disorder combined with neuropsychiatric diseases.

This invention belongs to the field of biomedical technology, specifically relating to the application of RSAD2, a novel target for macrophage inflammation regulation, in skin injury repair, and the compound PSB06126. Addressing the lack of specific targets and drugs in existing technologies capable of precisely regulating macrophage inflammatory responses and promoting tissue repair, this invention reveals for the first time that RSAD2 is specifically highly expressed in macrophages after skin injury, and drives the inflammatory response and fibrotic repair process by regulating the CMPK2 / mtDNA / NLRP3 inflammatory signaling pathway. Based on this mechanism, this invention provides a small molecule compound, PSB06126, that targets RSAD2. This compound can directly bind to RSAD2, inhibiting the overactivation of downstream pathways, thereby effectively reducing inflammation, accelerating wound healing, and reducing fibrotic scar formation in normal and diabetic skin injury models. This invention provides new targets and candidate compounds for the development of targeted drugs to treat skin healing disorders and other inflammation-related diseases.

This application provides an insulin analogue and its use, the insulin analogue comprising an A chain and a B chain; the sequence of the A chain includes: GIVEQCCTSICSLX aa14 QLENYCN, the B-chain sequence contains: FVNQHLCGSHLVEALY aa16 LVCGEY aa22 GF Y aa25 YTPY aa29 Y aa30 ; where X aa14 Selected from E, Y, K, or D, Y aa16 Selected from Y or H, Y aa22 Selected from Q, S, T, Y, or N, Y aa25 Selected from F, H, or K, Y aa29 Let R and Y be... aa30 It does not exist; the condition is: X aa14 and Y aa25 There is only one K in the insulin analogue. The insulin derivative obtained by the above-mentioned insulin analogue has significantly better in vitro INSR phosphorylation activity and glucose uptake activity than the control drug Icodec. The efficacy (PD) was evaluated using a type 1 diabetic rat model. It has the potential to be administered once a week or less frequently and has a significant hypoglycemic effect.

GLP-1 compounds for use in weight loss.

The present invention provides a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition comprising the compound, and a use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as shown in Formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, or racemate thereof. The compound of the present invention is capable of effectively reducing the synthesis of fatty acids and cholesterol esters, thereby alleviating the development and deterioration of metabolic diseases.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

The present application relates to a kind of efficient active separation and purification method and purposes of elaeagnus conferta polyphenol, comprising: elaeagnus conferta powder is extracted with ethanol solution, after ultrasonic extraction, centrifugal supernatant is obtained, repeat multiple times after being combined, concentrated by rotary evaporation, and obtain elaeagnus conferta polyphenol concentrated extract;Elaeagnus conferta polyphenol concentrated extract is centrifuged, and the supernatant is used as chromatography sample liquid;Chromatography sample liquid is added to Flash liquid chromatography by liquid sample loading mode, is separated by gradient elution mode to chromatographic column, and each elution component is collected in turn, and concentrated respectively;The concentrated solution of each elution component is added to chromatographic column again to carry out second gradient elution separation, and chromatographic column separation elution is repeated three times, and three kinds of purified elaeagnus conferta polyphenol components are obtained after freeze drying.The present application realizes the high-resolution fractionation elution of polyphenol monomer with high structural similarity by the synergistic regulation of mobile phase polarity gradient and elaeagnus conferta polyphenol molecular hydrophobic interaction.

The application discloses a kind of traditional Chinese medicine composition for weight loss assisted by acupoint catgut implantation and application thereof, the traditional Chinese medicine composition includes radix astragali 15-25 parts, fried atractylodes 10-18 parts, poria cocos 10-18 parts, lotus leaf 8-15 parts, bitter orange fruit 6-12 parts, divinum 6-12 parts, plantain 6-12 parts, and can be added coix seed, alisma orientalis, winter melon peel, giant knotweed by weight parts;Its preparation method is: part of medicinal material is extracted with water, part of medicinal material is extracted with alcohol, the rest lotus leaf is crushed and co-extracted with extract, and the powder is obtained after concentration and drying after being combined;The obtained traditional Chinese medicine composition is made into coating liquid with film-forming base, and is loaded on the surface of absorbable thread core by dipping or spraying, and the drug-loaded absorbable catgut is obtained after drying;The application realizes stable loading and sustained release of traditional Chinese medicine through slow-release layer design, avoids the decrease of mechanical properties of thread body and local adverse reactions, and improves the safety and durability of acupoint catgut implantation assisted weight loss.

The application discloses a dapagliflozin metformin sustained-release tablet, which comprises the following components: metformin hydrochloride, an isolation material, dapagliflozin propylene glycol monohydrate, a cosolvent, a lubricant, a diluent and a disintegrant. 90 The metformin hydrochloride is composed of three kinds of particles with different particle sizes, and the particle sizes D 90 of the three kinds of particles are 0.5-1.0 μm, 50-200 μm and 300-600 μm respectively. The weight composition ratio of the three kinds of particles is (0.5-1) : 1 : (0.5-1). The dapagliflozin metformin sustained-release tablet provided by the application has a longer action time, and can be uniformly and slowly released and chemically stable.

The application discloses a vitamin D-ovalbumin peptide composition, which comprises vitamin D3, ovalbumin peptide, a water-soluble auxiliary solubilizing stabilizer, an isotonic buffer regulator, an anti-oxidation bacteriostatic agent and a solvent in a residual amount, wherein the solvent is water. Compared with the prior art, the application has the advantages that a vitamin D-ovalbumin peptide composition with high stability and synergistic effect can be widely used in food, health products and medicines, and a preparation method and application thereof are provided.

This disclosure relates to a compound of formula (I), and a conjugate linked by this compound and pharmaceutical molecule. This disclosure also relates the making method of this compound, as well as the use of the said compound and the conjugate in making pharmaceutical related to cure or prevent the disease related to expression or over expression of gene in hepatocyte.

This invention belongs to the field of biomedicine and relates to a composition of intestinal flora regulators and mesenchymal stem cells and its application. The composition of this invention is applicable to the treatment of diabetes, effectively enhancing the therapeutic effect of mesenchymal stem cells in diabetes treatment, especially autoimmune type 1 diabetes, reducing pancreatic islet inflammation, and preserving more pancreatic β cells. It provides support for the clinical translation and application of mesenchymal stem cells and has promising application prospects.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.